NBI-31772 hydrate is a powerful inhibitor of the interaction between insulin-like growth factor (IGF) and IGF-binding proteins (IGFBPs). It acts as a nonpeptide ligand, effectively releasing bioactive IGF-I from the IGF-I/IGFBP-3 complex (Ki values for all six human subtypes range from 1-24 nM). This compound demonstrates significant anxiolytic and antidepressant-like effects [1] [2] [3].

NBI-31772 administered intracerebroventricularly (icv) in doses ranging from 5 to 100 μg to Sprague-Dawley rats subjected to the subtemporal middle cerebral artery occlusion (MCAO) model, either immediately or up to 3 hours post-MCAO, dose-dependently mitigated infarct size. Specifically, the maximum dose of 100 μg significantly diminished both overall and cortical infarct volumes, showcasing its protective efficacy against ischemic brain injury [3].